Five BioSpace NextGen companies debut on US markets in 2026, four actively hiring

BioSpace NextGen honorees accounted for about one third of the 14 U.S. biotech companies that went public in 2026.

The five companies together raised roughly $1.5 billion in IPO proceeds, including the full exercise of underwriters' options.

Four of the five firms are currently hiring, creating new opportunities for biopharma professionals.

Kardigan, which launched its IPO in January, raised $460 million and is developing a direct myosin activator called danicamtiv, now in a Phase 2b/3 trial for genetic dilated cardiomyopathy, alongside two other late‑stage programs.